Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism [Phase 3]

View source ↗

Summary

This document reports the completion of a Phase 3 study evaluating Androxal (enclomiphene citrate) for safety and efficacy in men with secondary hypogonadism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypogonadism

Drugs mentioned

• Androxal (enclomiphene citrate)

Snippet

Sponsor: Repros Therapeutics Inc. | Conditions: Secondary Hypogonadism | Phase 3 | Status: COMPLETED